MenQuadfi (Meningococcal Polysaccharide A, C, W-135 and Y Conjugate) for IM Injection

MenQuadfi is a meningococcal conjugate vaccine (MenACWY) that protects against meningococcal disease caused by serogroups A, C, W-135, and Y. This FDA-approved vaccine is recommended for preteens and teens starting at 11–12 years old, with a booster at 16 years, and for individuals at increased risk of meningococcal infection. Clinical data demonstrates 85–100% effectiveness for at least two years following vaccination. MenQuadfi works by stimulating the immune system to produce antibodies against the polysaccharide capsules of these four meningococcal serogroups, reducing the risk of invasive meningococcal meningitis. It may be administered alongside MenB vaccines (such as Bexsero or Trumenba) during the same visit for broader serogroup coverage. Healthcare providers recommend MenQuadfi as part of routine adolescent immunization schedules and for at-risk populations including college students, military recruits, and those with asplenia or complement deficiencies. Proper storage and administration by qualified healthcare professionals ensure optimal immunogenicity and safety.